Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × sacituzumab govitecan × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 27 Genitourinary 9 Thoracic 7 Head & Neck 4 Gynecologic 3 Gastrointestinal 3 CNS 3 Tumor-Agnostic 1 Other solid neoplasm 1 Endocrine 1

Conditions

Thyroid Carcinoma, Anaplastic 1

Interventions

lutetium Lu 177 dotatate 15 Magnetic Resonance Spectroscopy 13 gallium Ga 68 dotatate 8 Specimen Handling 8 Everolimus 8 pembrolizumab 7 Cisplatin 7 cabozantinib 6 Etoposide 5 177Lu-octreotide, DOTA(0)-Tyr(3)- 5 trametinib 4 lanreotide 4 dabrafenib 4 Fluorodeoxyglucose F18 4 surufatinib 3 olaparib 3 lenvatinib 3 fluorodopa F 18 3 cemiplimab 3 amino-acid, glucose, and electrolyte solution 3 X-Rays 3 Transurethral Resection of Prostate 3 Thyrotropin Alfa 3 Temozolomide 3 Somatostatin 3 Nivolumab 3 Lutetium-177 3 Iodine-131 3 Injections 3 Drug Therapy 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06235216 2024-11-01

SETHY

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Recruiting

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡